Speaker

Ingrid E. Wertz is a co-founder and the CEO of Lyterian Therapeutics. She obtained her undergraduate degree in Molecular and Cellular Biology from the University of California at Berkeley, performed her graduate studies at Genentech via an NIH Biotechnology Training Grant from U.C. Davis, and received her M.D. from Washington University in St. Louis as a Medical Scientist Training Program fellow. Following her graduate work, Ingrid joined Genentech where she co-initiated and led the Genentech Degrader Platform and contributed to numerous drug discovery programs, including those leading to the discovery of the FDA-approved BCL-2 inhibitor venetoclax and the selective estrogen receptor degrader giredistrant. that is currently in Phase 3 trials. Following Genentech, Ingrid joined Bristol Myers Squibb as the Executive Director of the Protein Homeostasis Center of Excellence. Dr. Wertz’s research is primarily focused on strategies to identify and harness endogenous protein homeostasis machinery for therapeutic benefit.

« Go Back